Loading stock data…
Coherus Oncology, Inc. (CHRS)
$1.37-0.05 (-3.52%)
Market ClosedLast close Sep 8
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Coherus Oncology, Inc. in the Healthcare sector is trading at $1.37 with a market capitalization of $219M. Wall Street consensus targets $7.75 (4 analysts), implying a +465.7% move over the next 12 months. The stock is currently near its 52-week low of $1.09, remaining 12.7% below its 200-day moving average. On fundamentals, Piotroski 6/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +465.7% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14.31M↑ | $12.31M↓ | $12.75M↑ | $11.57M↑ | $10.25M |
| Gross Profit | $10.06M↑ | $8.50M↓ | $8.70M↑ | $7.85M↑ | $6.86M |
| Operating Income | -$32.33M↑ | -$36.15M↑ | -$45.88M↓ | -$44.33M↑ | -$45.49M |
| Net Income | -$20.63M↑ | -$38.33M↓ | -$37.64M↓ | -$35.53M↓ | $297.77M |
Peer Comparison
JNJUNHPFE
Fundamentals
Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating f...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$219.39M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.95
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-217.19%
Volume
Today's trading volume
547,581
Recent News
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript
LOQTORZI sales surged 37% year-over-year as clinical programs advance toward key data readouts.
Coherus Oncology, Inc. Q2 2026 Earnings Call Summary
Moby summary of Coherus Oncology, Inc.'s Q2 2026 earnings call
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ...
Coherus Oncology Inc (CHRS) reports 15% LOQTORZI sales growth and advancing oncology pipeline, while managing significant cash reduction and legacy liabilities.
Coherus Oncology Q2 Earnings Call Highlights
Coherus Oncology (NASDAQ:CHRS) said it is approaching several clinical data disclosures in the second half of 2026, while reporting continued growth for its LOQTORZI treatment and lower operating expenses following the divestiture of its UDENYCA franchise. Chief Executive Officer Denny Lanfear said
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates
Coherus Oncology (CHRS) delivered earnings and revenue surprises of -337.50% and -45.57%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?